A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind,
placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.